Dimension Therapeutics, Inc
DMTX
DMTX was delisted on the 6th of November, 2017.
40 hedge funds and large institutions have $170M invested in Dimension Therapeutics, Inc in 2016 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 15 increasing their positions, 9 reducing their positions, and 8 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 9
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2% less funds holding
Funds holding: 41 → 40 (-1)
13% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 8
30% less capital invested
Capital invested by funds: $242M → $170M (-$72.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$3.62M |
| 2 |
AG
Artal Group
Luxembourg
|
+$788K |
| 3 |
JP Morgan Chase
New York
|
+$632K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$465K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$405K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$2.86M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$2.26M |
| 3 |
Goldman Sachs
New York
|
-$1.23M |
| 4 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$710K |
| 5 |
Norges Bank
Oslo,
Norway
|
-$564K |
DMTX Hedge Fund Activity: Q1 2016 in Review
40 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Dimension Therapeutics, Inc (DMTX) for Q1 2016, worth a combined $170M — down 30% from $242M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of DMTX and 7 opened new positions — a net loss of 1 holder — while 9 trimmed existing stakes and 15 added.
The largest buyer was RA Capital Management, adding an estimated $3.62M. The largest seller was Driehaus Capital Management, exiting entirely with an estimated $2.86M sold.
- 40 institutional investors held Dimension Therapeutics, Inc (DMTX) as of Q1 2016, down from 41 in Q4 2015.
- Funds reported $170M of Dimension Therapeutics, Inc stock for Q1 2016, down 30% quarter-over-quarter.
- 7 funds opened new Dimension Therapeutics, Inc positions in Q1 2016 and 8 closed out, a net change of -1 holder.
- The largest Dimension Therapeutics, Inc buyer in Q1 2016 was RA Capital Management, an estimated $3.62M added.
- The largest Dimension Therapeutics, Inc seller in Q1 2016 was Driehaus Capital Management, an estimated $2.86M sold.
Based on aggregated 13F filings for Q1 2016.